The impact of acute kidney injury stages on the outcomes of veno‐arterial extracorporeal membrane oxygenation

Background Although acute kidney injury (AKI) has been established as an independent risk factor for in‐hospital mortality for patients on veno‐arterial (V‐A) extracorporeal membranous oxygenation (ECMO), the impact of Kidney Disease Improving Global Outcomes (KDIGO) stages of AKI has yet to be eluc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Artificial organs 2024-07, Vol.48 (7), p.763-770
Hauptverfasser: Kallur, Akhil S., Armijo‐Alba, Julian, Russell, Jacqueline L., Sallam, Tariq, Bien‐Aime, Fred, Sanghavi, Kavya K., Garg, Mohil, Khan, Naveera, Bakri, Mouaz Haj, Zaghlol, Louay, Khan, Imran, El‐Akawi, Shadi, Llama, Adrian, Sawalha, Yazan, Trivedi, Suraj, Alassar, Aiman, Zaaqoq, Akram M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Although acute kidney injury (AKI) has been established as an independent risk factor for in‐hospital mortality for patients on veno‐arterial (V‐A) extracorporeal membranous oxygenation (ECMO), the impact of Kidney Disease Improving Global Outcomes (KDIGO) stages of AKI has yet to be elucidated as a risk factor. Methods We conducted a retrospective analysis of patient outcomes based on KDIGO stages of AKI at a single institution. The analysis was a cohort of 179 patients; 66 without AKI, 19 with stage 1 AKI, 18 with stage 2 AKI, and 76 with stage 3 AKI. Results Every 1‐year increase in age was associated with 4% increased odds of mortality at 30 days (95% confidence interval [CI] 1.01, 1.07; p = 0.004). The presence of AKI at any stage was associated with 59% increased odds of 30‐day mortality (95% CI 0.81, 3.10; p = 0.176). The presence of stage 1 AKI was associated with a 5% decreased odds of 30‐day mortality (95% CI 0.32, 2.89). The presence of stage 2 AKI (odds ratio [OR] 2.29, 95% CI 0.69, 7.55; p = 0.173) and stage 3 AKI (OR 1.68, 95% CI 0.81, 3.46; p = 0.164) was associated with increased odds of 30‐day mortality. Conclusion Based on our single‐center study, higher KDIGO stages of AKI likely have increased odds of mortality at 30 days. Larger studies are needed to confirm these findings. The impact of Kidney Disease Improving Global Outcomes (KDIGO) stages of AKI has yet to be elucidated as a risk factor. We conducted a single‐center retrospective analysis of patient outcomes based on KDIGO stages of AKI. Of 179 patients; 66 were without AKI, 19 were with stage 1 AKI, 18 were with stage 2 AKI, and 76 were with stage 3 AKI. Higher KDIGO stages of AKI likely have increased odds of mortality at 30 days.
ISSN:0160-564X
1525-1594
DOI:10.1111/aor.14714